cDNA microarray analysis of altered gene expression in Ara-C-treated leukemia cells

Area of Science:

• Molecular Biology
• Cancer Research
• Hematology

Background:

• Acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) exhibit differential responses to chemotherapy.
• Cytarabine (Ara-C) is a key chemotherapeutic agent with varying efficacy across leukemia types.
• Understanding differential gene expression is crucial for optimizing leukemia treatment strategies.

Purpose of the Study:

• To investigate the distinct molecular responses of ALL (CCRF-CEM) and CML (K562) cell lines to Ara-C treatment.
• To identify key genes and pathways involved in Ara-C-induced apoptosis and differentiation.
• To explore potential synergistic therapeutic strategies for CML.

Main Methods:

• Utilized cDNA microarrays for comprehensive gene expression profiling of CCRF-CEM and K562 cells.
• Administered Ara-C to induce apoptosis in CCRF-CEM cells and differentiation in K562 cells.
• Performed sequential treatment with Ara-C and L-asparaginase on K562 cells.

Main Results:

• CCRF-CEM cells showed down-regulation of chaperone genes upon Ara-C treatment.
• K562 cells exhibited up-regulation of hemoglobin genes and down-regulation of asparagine synthetase gene following Ara-C exposure.
• Sequential Ara-C and L-asparaginase treatment demonstrated synergistic inhibition of K562 cell growth.

Conclusions:

• Distinct gene expression patterns correlate with differential cellular responses to Ara-C in ALL and CML.
• Down-regulation of asparagine synthetase in K562 cells suggests a mechanism for enhanced sensitivity to L-asparaginase.
• Combination therapy with Ara-C and L-asparaginase holds promise for treating CML.